New metal-based drugs: spectral, electrochemical, DNA-binding and anticancer activity properties

Mustafa Çeşme*, Harun Muslu, Mehmet Tumer, Özge Güngör, Mine Altunbek, Mustafa Culha, Aysegul Golcu

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

The coordination compounds of antineoplastic chemotherapy drug of dacarbazine (DAC) with Zn(II) ([Zn(DAC)2] 3H2O; NGDCM1) and Cu(II) ([Cu(DAC)ClH2O]; NGDCM2) were synthesized and characterized using analytical and spectroscopic techniques. The electrochemical behaviors of the obtained new compounds and the starting active substance DAC were examined in detail. The interaction of all compounds with fish sperm double-stranded deoxyribonucleic acid (FSdsDNA) was investigated by measuring their binding constant (Kb) to FSdsDNA. Also, the competitive binding fluorescence spectroscopy studies with ethidium bromide (EtBr) were carried out. Furthermore, both compound’s anticancer activities were investigated on human lung cancer (A549) cells, and their effects were compared to other metals possessing antineoplastic drugs, including oxaliplatin and cisplatin.

Original languageEnglish
Pages (from-to)165-176
Number of pages12
JournalInorganic and Nano-Metal Chemistry
Volume54
Issue number2
DOIs
Publication statusPublished - 2024

Bibliographical note

Publisher Copyright:
© 2021 Taylor & Francis Group, LLC.

Keywords

  • DNA binding
  • Metal-based drugs
  • antineoplastic
  • dacarbazine

Fingerprint

Dive into the research topics of 'New metal-based drugs: spectral, electrochemical, DNA-binding and anticancer activity properties'. Together they form a unique fingerprint.

Cite this